These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 24330187)

  • 1. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
    Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
    Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
    Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable Chimerism and Long-Term Survival after Unrelated Umbilical Cord Blood Transplantation for Pediatric Hemophagocytic Lymphohistiocytosis: A Single-Center Experience.
    Patel SA; Allewelt HA; Troy JD; Martin PL; Driscoll TA; Prasad VK; Kurtzberg J; Page KM; Parikh SH
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1722-1728. PubMed ID: 28647558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
    Gonzalez-Llano O; Jaime-Pérez J; Cantu-Rodríguez O; Mancias-Guerra C; Gutierrez-Aguirre H; Herrera-Garza J; Gomez-Almaguer D
    Eur J Haematol; 2006 Oct; 77(4):341-4. PubMed ID: 16856932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine/Melphalan 100 mg/m
    Park HS; Lee JH; Lee JH; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1116-1121. PubMed ID: 30508593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients.
    Ouachée-Chardin M; Elie C; de Saint Basile G; Le Deist F; Mahlaoui N; Picard C; Neven B; Casanova JL; Tardieu M; Cavazzana-Calvo M; Blanche S; Fischer A
    Pediatrics; 2006 Apr; 117(4):e743-50. PubMed ID: 16549504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.
    Nishi M; Nishimura R; Suzuki N; Sawada A; Okamura T; Fujita N; Kanai R; Yano J; Adachi S; Yasumi T; Sato E; Yasutomo K; Ishii E; Ohga S
    Am J Hematol; 2012 Jun; 87(6):637-9. PubMed ID: 22488407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk for complications in patients with hemophagocytic lymphohistiocytosis who undergo hematopoietic stem cell transplantation: myeloablative versus reduced-intensity conditioning regimens.
    Schechter T; Naqvi A; Weitzman S
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1101-6. PubMed ID: 24871821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis.
    Cooper N; Rao K; Gilmour K; Hadad L; Adams S; Cale C; Davies G; Webb D; Veys P; Amrolia P
    Blood; 2006 Feb; 107(3):1233-6. PubMed ID: 16219800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
    Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2.
    Hamidieh AA; Pourpak Z; Yari K; Fazlollahi MR; Hashemi S; Behfar M; Moin M; Ghavamzadeh A
    Pediatr Transplant; 2013 Aug; 17(5):487-91. PubMed ID: 23714271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allogeneic hematopoietic stem cell transplantation for hemophagocytic syndrome].
    Sun R; Xiao J; Zhang J; Lu Y; Wei Z; Zhu H; Sun Y
    Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):94-8. PubMed ID: 24739718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
    Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.
    Marsh RA; Vaughn G; Kim MO; Li D; Jodele S; Joshi S; Mehta PA; Davies SM; Jordan MB; Bleesing JJ; Filipovich AH
    Blood; 2010 Dec; 116(26):5824-31. PubMed ID: 20855862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
    Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.